Actinium-225 for targeted α therapy: coordination chemistry and current chelation approaches

NA Thiele, JJ Wilson - Cancer biotherapy & radiopharmaceuticals, 2018 - liebertpub.com
The α-emitting radionuclide actinium-225 possesses nuclear properties that are highly
promising for use in targeted α therapy (TAT), a therapeutic strategy that employs α particle …

Carrier systems of radiopharmaceuticals and the application in cancer therapy

T Zhang, H Lei, X Chen, Z Dou, B Yu, W Su… - Cell Death …, 2024 - nature.com
Radiopharmaceuticals play a vital role in cancer therapy. The carrier of
radiopharmaceuticals can precisely locate and guide radionuclides to the target, where …

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

M Shi, V Jakobsson, L Greifenstein, PL Khong… - Frontiers in …, 2022 - frontiersin.org
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a
very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding …

Therapeutic radionuclides in nuclear medicine: current and future prospects

CH Yeong, M Cheng, KH Ng - Journal of Zhejiang University …, 2014 - pmc.ncbi.nlm.nih.gov
The potential use of radionuclides in therapy has been recognized for many decades. A
number of radionuclides, such as iodine-131 (131I), phosphorous-32 (32P), strontium-90 …